-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVG-111 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVG-111 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVG-111 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rinvecalinase Alfa in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rinvecalinase Alfa in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rinvecalinase Alfa in Acute Ischemic Stroke Drug Details: Rinvecalinase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Metastatic Colorectal Cancer Drug Details: NKTR-255 is under...
-
Product Insights
NewNet Present Value Model: DiaMedica Therapeutics Inc’s DM-199
Empower your strategies with our Net Present Value Model: DiaMedica Therapeutics Inc's DM-199 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNC-102 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNC-102 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNC-102 in Relapsed Multiple Myeloma Drug Details: SNC-102 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewVascular Dementias – Drugs In Development, 2024
Empower your strategies with our Vascular Dementias – Drugs In Development, 2024 report and make more profitable business decisions. Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. Vascular dementia can be caused by ischemic or hemorrhagic infarcts affecting multiple brain areas, including the anterior cerebral artery territory, the parietal lobes, or...
-
Product Insights
NewPancreatic Diseases – Drugs In Development, 2024
Empower your strategies with our Pancreatic Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatic diseases encompass a range of conditions that affect the pancreas, a vital organ located behind the stomach. The pancreas plays a crucial role in digestion and hormone regulation by producing enzymes for digestion and hormones like insulin and glucagon that regulate blood sugar levels. The Pancreatic Diseases drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewPancreatitis – Drugs In Development, 2024
Empower your strategies with our Pancreatitis – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatitis is an inflammation of the pancreas. Symptoms include nausea, vomiting, tenderness when touching the abdomen, weight loss, and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen, and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain. The Pancreatitis drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewIgA Nephropathy (Berger’s Disease) – Drugs In Development, 2024
Empower your strategies with our IgA Nephropathy (Berger's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. IgA nephropathy, also known as Berger's disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy...